| Unresponsiveness of colon cancer to BRAF (V600E) inhibition through feedback activation of EGFR A Prahallad, C Sun, S Huang, F Di Nicolantonio, R Salazar, D Zecchin, ... Nature 483 (7387), 100-103, 2012 | 2267 | 2012 |
| Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer F Di Nicolantonio, M Martini, F Molinari, A Sartore-Bianchi, S Arena, ... Journal of clinical oncology 26 (35), 5705-5712, 2008 | 2201 | 2008 |
| Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer S Misale, R Yaeger, S Hobor, E Scala, M Janakiraman, D Liska, E Valtorta, ... Nature 486 (7404), 532-536, 2012 | 2112 | 2012 |
| Liquid biopsy: monitoring cancer-genetics in the blood E Crowley, F Di Nicolantonio, F Loupakis, A Bardelli Nature reviews Clinical oncology 10 (8), 472-484, 2013 | 2054 | 2013 |
| Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study M Moroni, S Veronese, S Benvenuti, G Marrapese, A Sartore-Bianchi, ... The lancet oncology 6 (5), 279-286, 2005 | 1184 | 2005 |
| Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients G Siravegna, B Mussolin, M Buscarino, G Corti, A Cassingena, ... Nature medicine 21 (7), 795-801, 2015 | 1162 | 2015 |
| Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti–epidermal growth factor receptor antibody therapies S Benvenuti, A Sartore-Bianchi, F Di Nicolantonio, C Zanon, M Moroni, ... Cancer research 67 (6), 2643-2648, 2007 | 1097 | 2007 |
| A molecularly annotated platform of patient-derived xenografts (“xenopatients”) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer A Bertotti, G Migliardi, F Galimi, F Sassi, D Torti, C Isella, D Corà, ... Cancer discovery 1 (6), 508-523, 2011 | 1047 | 2011 |
| PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies A Sartore-Bianchi, M Martini, F Molinari, S Veronese, M Nichelatti, ... Cancer research 69 (5), 1851-1857, 2009 | 945 | 2009 |
| Reversible and adaptive resistance to BRAF (V600E) inhibition in melanoma C Sun, L Wang, S Huang, GJJE Heynen, A Prahallad, C Robert, ... Nature 508 (7494), 118-122, 2014 | 938 | 2014 |
| Association of KRAS p. G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab W De Roock, DJ Jonker, F Di Nicolantonio, A Sartore-Bianchi, D Tu, ... Jama 304 (16), 1812-1820, 2010 | 900 | 2010 |
| Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer A Bardelli, S Corso, A Bertotti, S Hobor, E Valtorta, G Siravegna, ... Cancer discovery 3 (6), 658-673, 2013 | 720 | 2013 |
| Biomarkers predicting clinical outcome of epidermal growth factor receptor–targeted therapy in metastatic colorectal cancer S Siena, A Sartore-Bianchi, F Di Nicolantonio, J Balfour, A Bardelli Journal of the National Cancer Institute 101 (19), 1308-1324, 2009 | 717 | 2009 |
| Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth G Germano, S Lamba, G Rospo, L Barault, A Magrì, F Maione, M Russo, ... Nature 552 (7683), 116-120, 2017 | 631 | 2017 |
| Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution S Misale, F Di Nicolantonio, A Sartore-Bianchi, S Siena, A Bardelli Cancer discovery 4 (11), 1269-1280, 2014 | 526 | 2014 |
| Tumor heterogeneity and lesion-specific response to targeted therapy in colorectal cancer M Russo, G Siravegna, LS Blaszkowsky, G Corti, G Crisafulli, ... Cancer discovery 6 (2), 147-153, 2016 | 427 | 2016 |
| Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus F Di Nicolantonio, S Arena, J Tabernero, S Grosso, F Molinari, ... The Journal of clinical investigation 120 (8), 2858-2866, 2010 | 408 | 2010 |
| Adaptive mutability of colorectal cancers in response to targeted therapies M Russo, G Crisafulli, A Sogari, NM Reilly, S Arena, S Lamba, A Bartolini, ... Science 366 (6472), 1473-1480, 2019 | 384 | 2019 |
| EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer V Amodio, R Yaeger, P Arcella, C Cancelliere, S Lamba, A Lorenzato, ... Cancer discovery 10 (8), 1129-1139, 2020 | 366 | 2020 |
| Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3 C Sun, S Hobor, A Bertotti, D Zecchin, S Huang, F Galimi, F Cottino, ... Cell reports 7 (1), 86-93, 2014 | 360 | 2014 |
Salvatore SienaUniversità degli Studi di Milano e Ospedale Niguarda, Milano, ItalyVerified email at unimi.it
